|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eccles SA and Welch DR: Metastasis: Recent
discoveries and novel treatment strategies. Lancet. 369:1742–1757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin SY, Lee YX, Yu SL, Chang GC and Chen
JJ: Phosphatase of regenerating liver-3 inhibits invasiveness and
proliferation in non-small cell lung cancer by regulating the
epithelial-mesenchymal transition. Oncotarget. 7:21799–21811.
2016.PubMed/NCBI
|
|
7
|
Yao Y, Shi M, Liu S and Li Y, Guo K, Ci Y,
Liu W and Li Y: MARVELD1 modulates cell surface morphology and
suppresses epithelial-mesenchymal transition in non-small cell lung
cancer. Mol Carcinog. 55:1714–1727. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V, Lee RC, Lavanway A, Williams PT
and Jewell D: MicroRNAs and other tiny endogenous RNAs in C.
elegans. Curr Biol. 13:807–818. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong
Y, Zhou Y, Zhang CY and Chen X: Tumor-suppressive miR-218-5p
inhibits cancer cell proliferation and migration via EGFR in
non-small cell lung cancer. Oncotarget. 7:28075–28085.
2016.PubMed/NCBI
|
|
10
|
Ma N, Zhang W, Qiao C, Luo H, Zhang X, Liu
D, Zang S, Zhang L and Bai J: The tumor suppressive role of
miRNA-509-5p by targeting FOXM1 in non-small cell lung cancer. Cell
Physiol Biochem. 38:1435–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou L, Di Q, Sun B, Wang X, Li M and Shi
J: MicroRNA-194 restrains the cell progression of non-small cell
lung cancer by targeting human nuclear distribution protein C.
Oncol Rep. 35:3435–3444. 2016.PubMed/NCBI
|
|
12
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen HC, Chen GH, Chen YH, Liao WL, Liu
CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and
pathway alterations in nasopharyngeal carcinoma. Br J Cancer.
100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y,
Fan S and Liu Y: MicroRNA-187, down-regulated in clear cell renal
cell carcinoma and associated with lower survival, inhibits cell
growth and migration though targeting B7-H3. Biochem Biophys Res
Commun. 438:439–444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bloomston M, Frankel WL, Petrocca F,
Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce
CM: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Casanova-Salas I, Rubio-Briones J,
Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A,
Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of
miR-187 and miR-182 as biomarkers of early diagnosis and prognosis
in patients with prostate cancer treated with radical
prostatectomy. J Urol. 192:252–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y and Stallings RL: Differential
patterns of microRNA expression in neuroblastoma are correlated
with prognosis, differentiation, and apoptosis. Cancer Res.
67:976–983. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F
and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer
(NSCLC) development through down-regulation of BCL6. Biochem
Biophys Res Commun. 471:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu
Y, Shi J, Sun X, Liu Y, Ding Y, et al: MicroRNA-187, a downstream
effector of TGFβ pathway, suppresses Smad-mediated
epithelial-mesenchymal transition in colorectal cancer. Cancer
Lett. 373:203–213. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, An H, Wang B, Liao Q, Li W, Jin X,
Cui S, Zhang Y, Ding Y and Zhao L: miR-133a represses tumour growth
and metastasis in colorectal cancer by targeting LIM and SH3
protein 1 and inhibiting the MAPK pathway. Eur J Cancer.
49:3924–3935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park SY, Lee JH, Ha M, Nam JW and Kim VN:
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat
Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y
and Li D: Long non-coding RNA NEAT1 promotes non-small cell lung
cancer progression through regulation of miR-377-3p-E2F3 pathway.
Oncotarget. 7:51784–51814. 2016.PubMed/NCBI
|
|
26
|
Zhang X, Wang C, Shan S, Liu X, Jiang Z
and Ren T: TLR4/ROS/miRNA-21 pathway underlies lipopolysaccharide
instructed primary tumor outgrowth in lung cancer patients.
Oncotarget. 7:42172–42182. 2016.PubMed/NCBI
|
|
27
|
Gregory PA, Bracken CP, Bert AG and
Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal
transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chao A, Lin CY, Lee YS, Tsai CL, Wei PC,
Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of
ovarian cancer progression by microRNA-187 through targeting
Disabled homolog-2. Oncogene. 31:764–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li NY, Weber CE, Wai PY, Cuevas BD, Zhang
J, Kuo PC and Mi Z: An MAPK-dependent pathway induces
epithelial-mesenchymal transition via Twist activation in human
breast cancer cell lines. Surgery. 154:404–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomlinson DC, Baxter EW, Loadman PM, Hull
MA and Knowles MA: FGFR1-induced epithelial to mesenchymal
transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS One.
7:e389722012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gui T, Sun Y, Shimokado A and Muragaki Y:
The roles of mitogen-activated protein kinase pathways in
TGF-β-induced epithelial-mesenchymal transition. J Signal
Transduct. 2012:2892432012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ning J, Liu W, Zhang J, Lang Y and Xu S:
Ran GTPase induces EMT and enhances invasion in non-small cell lung
cancer cells through activation of PI3K-AKT pathway. Oncol Res.
21:67–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X, Liu T, Bai Y, Liao H, Qiu S, Chang
Z, Liu Y, Yan X and Guo H: Polymerase I and transcript release
factor acts as an essential modulator of glioblastoma
chemoresistance. PLoS One. 9:e934392014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Massagué J: TGFβ signalling in context.
Nat Rev Mol Cell Biol. 13:616–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jansa P, Mason SW, Hoffmann-Rohrer U and
Grummt I: Cloning and functional characterization of PTRF, a novel
protein which induces dissociation of paused ternary transcription
complexes. EMBO J. 17:2855–2864. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cohen AW, Hnasko R, Schubert W and Lisanti
MP: Role of caveolae and caveolins in health and disease. Physiol
Rev. 84:1341–1379. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hamoudane M, Maffioli S, Cordera R, Maggi
D and Salani B: Caveolin-1 and polymerase I and transcript release
factor: New players in insulin-like growth factor-I receptor
signaling. J Endocrinol Invest. 36:204–208. 2013.PubMed/NCBI
|
|
38
|
Aboulaich N, Ortegren U, Vener AV and
Strålfors P: Association and insulin regulated translocation of
hormone-sensitive lipase with PTRF. Biochem Biophys Res Commun.
350:657–661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gould ML, Williams G and Nicholson HD:
Changes in caveolae, caveolin, and polymerase 1 and transcript
release factor (PTRF) expression in prostate cancer progression.
Prostate. 70:1609–1621. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Aung CS, Hill MM, Bastiani M, Parton RG
and Parat MO: PTRF-cavin-1 expression decreases the migration of
PC3 prostate cancer cells: Role of matrix metalloprotease 9. Eur J
Cell Biol. 90:136–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nassar ZD, Moon H, Duong T, Neo L, Hill
MM, Francois M, Parton RG and Parat MO: PTRF/Cavin-1 decreases
prostate cancer angiogenesis and lymphangiogenesis. Oncotarget.
4:1844–1855. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng F, Joshi B and Nabi IR: Galectin-3
overrides PTRF/Cavin-1 reduction of PC3 prostate cancer cell
migration. PLoS One. 10:e01260562015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bai L, Deng X, Li Q, Wang M, An W, Deli A,
Gao Z, Xie Y, Dai Y and Cong YS: Down-regulation of the cavin
family proteins in breast cancer. J Cell Biochem. 113:322–328.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu L, Xu HX, Wang WQ, Wu CT, Chen T, Qin
Y, Liu C, Xu J, Long J, Zhang B, et al: Cavin-1 is essential for
the tumor-promoting effect of caveolin-1 and enhances its
prognostic potency in pancreatic cancer. Oncogene. 33:2728–2736.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gámez-Pozo A, Sánchez-Navarro I, Calvo E,
Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M,
Madero R, Espinosa E, et al: PTRF/cavin-1 and MIF proteins are
identified as non-small cell lung cancer biomarkers by label-free
proteomics. PLoS One. 7:e337522012. View Article : Google Scholar : PubMed/NCBI
|
